Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
Homerun Resources Inc. Advances Solar Glass Project Financing with Letter of Intent from Leading European Project Finance Bank for up to 170 Million Euros
Transition Metals Commences 2026 Exploration Program at Pike Warden Epithermal Gold-Silver and Porphyry Copper Project, Yukon
Infill Drilling Significantly Widens and Extends Near Surface Gold Mineralisation at Gemdale Gold's Pontio Gold Project, Finland
SAGA Metals Reports Assays from R-0055 to R-0057 with Intercepts Including 53.72% Fe2O3, 8.24% TiO2, 0.377% V2O5 from 2026 Drilling at Radar Critical Minerals Project in Labrador
